GeneNews Attending 2012 BIO International Convention
TORONTO, CANADA (June 19, 2012):
GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, is exhibiting at the 2012 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology is taking place June 18-21, 2012 at the Boston Convention and Exhibition Center. GeneNews is participating at the invitation of the Ontario government and is hosting a booth in the Ontario Pavilion (booth # 635).
"We are pleased to be at BIO as part of the Ontario mission to showcase innovative companies. This recognition and support is appreciated, following closely after our successful rights offering and the launch of our lead product, ColonSentry®, in the United States," said Gailina J. Liew, President & Chief Operating Officer of GeneNews.
The Sentinel Principle®, a platform technology discovered and developed by GeneNews, is based on the concept that all clinical conditions and body states, including those resulting from disease or in response to treatment, generate characteristic gene expression signatures in the blood as a result of the constant and dynamic physiological interaction of blood with the cells, tissues and organs of the human body. GeneNews is targeting the applications of its Sentinel Principle® platform to address unmet clinical needs, enable early disease detection and improve disease management. This technology is the basis of GeneNews' initial product, ColonSentry®, the world's first blood test for colorectal cancer, recently launched in the states of New York and New Jersey by the Company's marketing partner, Enzo Clinical Labs. GeneNews' broad global patent portfolio includes issued foundational patents and pending patents in diverse disease areas such as cancer, cardiovascular, neurological and inflammatory conditions.
GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage a range of diseases or medical conditions from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry®, is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry®, go to www.GeneNews.com or www.ColonSentry.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.